Skip to main content
Revive Therapeutics Ltd. logo

Revive Therapeutics Ltd. — Investor Relations & Filings

Ticker · RVV ISIN · CA7615161030 LEI · 967600MT7D67TXWXB884 CSE Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2022-09-14 Regulatory Filings
Country CA Canada
Listing CSE RVV

About Revive Therapeutics Ltd.

https://revivethera.com/

Revive Therapeutics is a life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases and rare disorders. The company's pipeline includes the investigation of Bucillamine for public health medical emergencies and rare inflammatory disorders, alongside the advancement of Psilocybin-based therapeutics. Revive prioritizes leveraging FDA regulatory incentives, such as Orphan Drug and Fast Track designations, to accelerate its drug development programs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the submission of an amended Phase 3 COVID-19 study protocol to the FDA by Revive Therapeutics. It discusses clinical trial protocol changes, regulatory interactions, and potential future steps but does not contain any financial data, earnings information, or detailed report content. It is an update on a clinical trial and regulatory submission rather than a financial report or management discussion. The document is not a report itself but an announcement of a regulatory filing related to clinical trial protocol. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-09-14 English
Notice of meeting - English.pdf
Regulatory Filings
2022-08-19 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release providing an update on a Phase 3 clinical trial for a drug related to COVID-19. It discusses changes to the study protocol and endpoints, regulatory interactions with the FDA, and general company information. There are no financial statements, earnings data, or detailed financial analysis. The document is not a report itself but an announcement/update about clinical trial progress. It does not fit into categories related to financial reports, governance, or shareholder matters. It is a regulatory announcement about clinical trial progress and regulatory discussions, which aligns best with Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-08-16 English
Notice of the meeting and record date (amended) - English.pdf
Regulatory Filings
2022-07-30 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release providing an update on a Phase 3 clinical trial for a drug related to COVID-19. It discusses unblinded data analysis, protocol amendments, and regulatory interactions with the FDA. There are no financial statements, earnings data, or detailed financial analysis. The content is focused on clinical trial progress and regulatory status rather than financial results or corporate governance. The document length is about 4955 characters, which is relatively short and typical for a press release or update. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing or certification. It is an update on clinical trial progress, which is best classified as a Regulatory Filings (RNS) type, as it is a general regulatory announcement that does not fit other specific categories.
2022-07-25 English
Notice of the meeting and record date (amended) - English.pdf
Regulatory Filings
2022-06-29 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.